New York: The US Food and Drug Administration has approved two pills developed for adult lung cancer patients.
Lung cancer is the second most common type of malignancy, causing a large number of deaths worldwide each year.
Every year November is observed as Lung Cancer Awareness Month to spread awareness about lung cancer.
AstraZeneca’s Amfenzi and Amjudo tablets have been approved for the treatment of adult lung cancer patients in the US following successful trial results to prevent the progression of malignant lung cancer. ( IMFINZI AND IMJUDO).
of a foreign news agency According to the report These drugs and platinum-based chemotherapy are approved in the US for the treatment of adult patients with ‘stage four non-small cell’ lung cancer.
The approval given by the US Food and Drug Administration (FDA) was based on the successful results of the Poseidon phase three trial.
Lung cancer is the second most commonly diagnosed cancer in the United States, with more than 236,000 patients expected to be diagnosed this year.
( IMFINZI AND IMJUDO) During the trial of these drugs, patients were first given five doses of Amjudo and Amfenzi, followed by four doses of platinum-based chemotherapy, which resulted in a reduction in patient mortality.
According to an estimate, 33% of patients survived for two years, while the mortality of chemotherapy patients actually decreased by 22%.